Bone Therapeutics Reports Results of Viscosupplement Study

Bone Therapeutics’ first efficacy study of the JTA-004 viscosupplement to treat knee osteoarthritis showed that a single injection delivered higher pain reduction between baseline and six months post-treatment vs. a reference product (hylan G-F 20).

JTA-004 is a patented, non-cellular viscosupplement product for the treatment of knee...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us